A recent research report published by MarkNtel Advisors cites that the China Colorectal Cancer Market is expecting around 3% CAGR during 2022-27. The rising patient pool of colorectal cancer (CRC) across China, owing to various reasons like lifestyle changes, increasing elderly population, growing nationwide urbanization, high intake of red meat, and lack of screening, among others, is instigating the need to enhance the existing medications required for its treatment.
The leading players participating in the market are conducting rigorous research & development activities with immense government support through substantial investments & favorable policies to test & implement novel therapies with multiple medications.
Additionally, since CRC is one of the leading causes of cancer-related deaths, various pharmaceutical companies across China are working toward introducing advanced drugs to address the diverse requirements
Mounting Consumer Awareness about the Effectiveness of Immunotherapies to Boost the Market
Among various types of CRC treatment, immunotherapy drugs like Bevacizumab, Cetuximab, & Panitumumab are anticipated to contribute substantially to the market growth during 2022-27, principally on the back of their benefits like no specificity or toxic side effects and better resistance in the body to fight cancer.
Bevacizumab, in combination with chemotherapy drugs, is being used as first or second-line treatment for Chinese CRC patients with no previous record of bevacizumab & has displayed better efficacy than chemotherapy alone.
Moreover, these drugs help the immune system keep itself from attacking the healthy cells & only target cancer cells. Hence, the growing awareness among patients about these drugs & benefits is propelling the overall growth of the China Colorectal Cancer Market.
The leading players in the China Colorectal Cancer Market are Amgen China, Bristol-Myers Squibb, Bayer AG, Merck KGaA, Roche (China) Co., Ltd., Eli Lilly & Company, Sanofi China, Taiho Pharmaceutical, Novartis AG, and Pfizer Inc.
Key Questions Answered in the Research Report